D. Boral Capital argues that Biomea Fusion’s (BMEA) presentations at the 22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease “highlight icovamenib’s groundbreaking potential as a disease-modifying therapy for diabetes” and contends that preclinical findings and the unique mechanism of action position Biomea’s icovamenib as “a front-runner in addressing the unmet needs in diabetes care.” The firm maintains a Buy rating and $128 price target on Biomea shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMEA:
- Closing Bell Movers: Oracle slips 8% after Q2 earnings miss, disappointing guide
- Biomea Fusion announces preliminary COVALENT-103 study data
- Biomea Fusion’s icovamenib shows efficacy in Type 2 diabetes trial
- Short Report: Archer Aviation shorts at seven-week high
- Biomea Fusion price target raised to $19 from $10 at Piper Sandler